Opioid Agonist Treatment is the cornerstone of minimising harms related to opioid use, however its uptake is limited by a tightly regulated and stigmatising treatment environment. The COVID-19 pandemic necessitated relaxation of some treatment restrictions, with global evidence pointing to more patient-centred care in this time. In light of local evidence to support the safety of increased access to takeaway doses and a precedent set by the Substance Abuse and Mental Health Administration, we recommend adoption of the Australian Interim Medication Assisted Treatment of Opioid Dependence guidance in Australia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drugpo.2024.104420 | DOI Listing |
Publication Analysis
Top Keywords
opioid agonist
8
agonist treatment
8
treatment opioid
8
treatment
5
time australia
4
australia increase
4
increase doses
4
opioid
4
doses opioid
4
treatment cornerstone
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!